Clinical Trial Update: A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. [Phase 4]

View source ↗

Summary

Phase IV trial evaluating the safety, tolerability, and effectiveness of rivastigmine transdermal patch (15 cm²) in patients with severe Alzheimer's disease; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rivastigmine patch (15 cm²) (rivastigmine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2024-05-31